Graphee CEO Shim Woon-sep presents evidence-based innovation strategy at Korea 3D Printing Convergence Medical Society conference

Graphee CEO Shim Woon-seop delivered a keynote address at the 14th Annual Conference of the Korea 3D Printing Convergence Medical Society, held May 15 at Seoul National University's Global Engineering Education Center. Speaking on "Where Evidence-Based Research Meets Medical Innovation," Shim argued that the medical 3D printing industry must evolve beyond a tool-focused model of equipment sales and printing services toward a trust-based industry built on clinical evidence, data accumulation, standardization, and regulatory compliance. He highlighted Graphee's Shape Memory Aligner (SMA) technology as a case study in integrated system development, encompassing materials, process standardization, clinical data, and user training.

Shim's diagnosis that most medical 3D printing companies remain stuck in a "tool industry" phase reflects a structural gap that has limited the sector's commercial credibility. Graphee's strategy directly addresses the medical-dental vertical's core challenge: regulatory bodies and clinicians demand longitudinal clinical data, not novel hardware. By building an "Evidence Loop" spanning study design, data collection, peer-reviewed publication, and standardization, Graphee is attempting to create the switching-cost structure that turns a novel material into an embedded clinical solution. This mirrors the aerospace qualification grind pattern, but compressed for the faster medical-device regulatory pathway.

The emphasis on evidence-based research over technology novelty is a pragmatic acknowledgment that medical device startups fail not from technical weakness but from regulatory delays, market distrust, and lack of global standards. Shim's call for an industry-academia-government ecosystem to build transparent, standardized infrastructure is a realistic prescription for a sector where trust, not print speed, determines commercial viability. For Graphee, the immediate next step is expanding its SCI publication pipeline and clinical trial data to support regulatory submissions in target markets beyond Korea, particularly the US and EU, where the SMA technology's force-consistency claims will face rigorous scrutiny.